著者
Abbas Mohammadi Motomichi Koyama Gregory Gerstein Hans Jürgen Maier Hiroshi Noguchi
出版者
The Iron and Steel Institute of Japan
雑誌
ISIJ International (ISSN:09151559)
巻号頁・発行日
pp.ISIJINT-2019-510, (Released:2020-05-25)
参考文献数
42
被引用文献数
4

Hydrogen-assisted crack growth of pre-strained twinning-induced plasticity (TWIP) steel was investigated using artificial defects (micro-drilled holes), which acted as artificial crack initiation sites. Hydrogen was introduced into the specimens by electrochemical hydrogen charging during slow strain rate tensile test. The quasi-cleavage crack propagation observed was due to repeated crack initiation near the crack tip and subsequent coalescence. Crack initiation near the crack tip occurred after plastic deformation of the crack tip, and pre-straining facilitated plasticity-driven crack initiation. The early stage of plasticity-driven crack growth was sensitive to the crack length and remote stress level. Accordingly, the crack growth rate in the early stage increased with the increase in the initial defect size. In the following stage of the crack growth, the crack growth rate exhibited a complicated trend with respect to the crack length, which is possibly due to the plastic-wake-altered stress field around the crack tip, which depends on the initial defect size.
著者
Takanori Mei Hiroshi Noguchi Kimitaka Suetsugu Yu Hisadome Keizo Kaku Yasuhiro Okabe Satohiro Masuda Masafumi Nakamura
出版者
The Pharmaceutical Society of Japan
雑誌
Biological and Pharmaceutical Bulletin (ISSN:09186158)
巻号頁・発行日
vol.43, no.10, pp.1600-1603, 2020-10-01 (Released:2020-10-01)
参考文献数
16
被引用文献数
3

Vonoprazan fumarate (vonoprazan) is a new kind of acid suppressant with potent acid inhibitory effects. Therefore, it has been administered to kidney transplant recipients for treatment or prophylaxis of steroid ulcers, refractory peptic ulcers, and gastroesophageal reflux disease. Because tacrolimus, which is a well-established immunosuppressant for kidney transplantation, and vonoprazan share the CYP3A4 system for metabolism, drug interactions are anticipated upon simultaneous administration. We retrospectively analyzed 52 kidney transplant recipients who were converted from rabeprazole, which has a small effect on the tacrolimus trough blood concentration (C0), to vonoprazan between August 2016 and July 2019. We compared the tacrolimus C0/tacrolimus dose (C0/D) before and after conversion and serum liver enzymes, serum total bilirubin, and the estimated glomerular filtration rate (eGFR). As a result, mean tacrolimus C0/D before and after conversion was 1.98 ± 1.02 and 2.19 ± 1.15 (ng/mL)/(mg/d), respectively, (p < 0.001). Additionally, mean aspartate transaminase (AST) before and after conversion was 18.6 ± 4.2 and 19.6 ± 5.2 IU/L, respectively, (p = 0.037). Mean alanine transaminase (ALT) before and after conversion was 15.8 ± 5.5 and 17.6 ± 7.1 IU/L, respectively, (p = 0.007). Mean eGFR before and after conversion was 50.6 ± 14.4 and 51.4 ± 14.7 mL/min/1.73 m2, respectively (p = 0.021). Mean AST, ALT, and eGFR were slightly but significantly elevated within normal ranges after conversion. In conclusion, our study suggests that the mean tacrolimus C0/D was elevated significantly by converting from rabeprazole to vonoprazan, but it had little clinical significance. Vonoprazan can be administered safely to kidney transplant recipients receiving tacrolimus.